Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 4, 1999, Pages 303-306

  Lopez, A M ^a   Wallace, L ^a   Dorr, R T ^a   Koff, M ^a   Hersh, E M ^a   Alberts, D S ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy; Dimethylsulfoxide; Palmar plantar dysesthesia

Indexed keywords

DIMETHYL SULFOXIDE; DOXORUBICIN; LIPOSOME;

ADULT; AGED; ARTICLE; BLISTER; CANCER CHEMOTHERAPY; CASE REPORT; CONTROLLED STUDY; DESQUAMATION; ERYTHEMA; EXTRAVASATION; FEMALE; FOOT DISEASE; HAND DISEASE; HAND FOOT SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEIOMYOSARCOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; PRIORITY JOURNAL; PRURITUS; SKIN DISEASE; SKIN METASTASIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DIMETHYL SULFOXIDE; DOXORUBICIN; ERYTHEMA; FEMALE; FOOT; HAND; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; PARESTHESIA; POLYETHYLENE GLYCOLS; SYNDROME;

EID: 0032802955     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050981     Document Type: Article

References (24)

1. Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, Del Mastro L, Garrone O, Rosso R, Dini D (1995) Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851
2. Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80: 249
3. Comandone A, Bretti S, La Grotta G, Manzoni S, Bonardi G, Berardo R, Bumma C (1993) Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment. Anticancer Res 13: 1781
4. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R (1990) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 8: 57
5. Frei E, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585
6. Gabizon A, Papahadjopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85: 6949
7. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J (1995) Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75: 2169
8. Henderson IC, Hayes DF, Gelman R (1988) Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 6: 1501
9. James ND, Coker RJ, Tomlinson D, Harris JR, Gompels M, Pinching AJ, Stewart JS (1994) Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin Oncol (R Coll Radiol) 6: 294
10. Larson DL (1982) Treatment of tissue extravasation by antitumor agents. Cancer 49: 1796
11. Leichman CG, Leichman L, Spears CP, Rosen PJ, Jeffers S, Groshen S (1993) Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 85: 41
12. Levine LE, Medenica MM, Lorincz AL, Soltani K, Raab B, Ma A (1985) Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 121: 102
13. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324: 808
14. Lokich JJ, Moore C (1984) Chemotherapy-associated palmarplantar erythrodysesthesia syndrome. Ann Intern Med 101: 798
15. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 7: 425
16. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987
17. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36: 55
18. Olver IN, Aisner J, Hament A, Buchanan L, Bishop JF, Kaplan RS (1988) A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6: 1732
19. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460
20. Simpson JK, Miller RF, Spittle MF (1993) Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma. Clin Oncol (R Coll Radiol) 5: 372
21. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13: 1777
22. Vogelzang NJ, Ratain MJ (1985) Cancer chemotherapy and skin changes. Ann Intern Med 103: 303
23. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710
24. Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, Davis TE, Fazzini E, Cheuvart B, Horton J (1992) Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 10: 1